Driehaus Capital Management focuses on global, emerging markets, US growth equity, and alternative investment strategies, with a particular emphasis on small- and micro-cap stocks and emerging markets. Their strategy involves an active management approach to identify companies experiencing significant positive turning points in growth and earnings, aiming to capitalize on market mispricings and maximize capital appreciation.
100% of their portfolio is in Biotech & Life Sciences. They made 2 investments in the last 12 months. Average disclosed round size is $97.4M (across 4 rounds with reported amounts).
Portfolio
4
Fund Size
$28.7B
Top Stage
Series C
Last 12 Mo
2
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
4 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Congruence Therapeutics | Series B | $39.5M | Mar 2026 |
 Crescent Biopharma | Growth | $200M | Jun 2025 |
| Congruence Therapeutics | Series A | $50M | Feb 2022 |
| CC2i Genomics | Series C | $100M | Apr 2021 |
Top Co-Investors
Amplitude Ventures2 shared
OrbiMed2 shared
Investissement Quebec2 shared
Casdin Capital1 shared
NFX1 shared
Duquesne Family Office1 shared
Section 321 shared
Silver Lake1 shared
LionBird Ventures1 shared
Wellington Management1 shared
Fairmount1 shared
BVF Partners LP1 shared
Paradigm BioCapital1 shared
RTW Investments1 shared
Blackstone Inc.1 shared
Frazier Life Sciences1 shared
Commodore Capital1 shared
Perceptive Advisors1 shared
Deep Track Capital1 shared
Last updated: 12 April 2026